Regulatory changes to the nursing home industry for this year may seem small individually, but together, they reflect broader initiatives sought by the ...
Zacks Investment Research on MSN
CareDx reports positive data for AlloHeme in AML and MDS post HCT
CareDx CDNA recently announced clinical validation data supporting AlloHeme, its next-generation, blood-based monitoring test designed to predict relapses in patients with acute myeloid leukemia (AML) ...
A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results